MedTrace Logo

Oncogeriatric Intervention and Follow-up at Home

NCT02837679 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2020-04-29

No results posted yet for this study

Summary

The study is a randomized study of patients living in four municipalities in Eastern Jutland. After geriatric assessment half of the patients will be offered a tailor-made intervention in their homes. The follow-up will last for at least 90 days and include treatment of the patients' multimorbidity, e.g. of dehydration, anaemia, infections, and malnutrition. The other half of the patients, the results of the assessment and recommendations will be given to the patients and their general practitioner.

The primary efficacy variables are accomplishment of planned cancer treatment, reduction of complications and admissions to hospital and increased quality of life,.

If geriatric assessment and a tailor-made follow-up result in a better quality of life with less complications and admissions the offer may be extended to a longer period, younger age groups and other cancer diagnoses.

Conditions

  • Neoplasms
  • Geriatric Assessment
  • Lung Neoplasms
  • Colorectal Neoplasms
  • Head and Neck Neoplasms
  • Gastrointestinal Neoplasms
  • Geriatrics
  • Polypharmacy
  • Quality of Life

Interventions

OTHER

Geriatric Follow up

Sponsors & Collaborators

  • Danish Cancer Society

    collaborator OTHER

  • Aarhus University Hospital

    lead OTHER

Principal Investigators

  • Marianne Ørum, MD · Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2019-09-30
Completion
2023-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02837679 on ClinicalTrials.gov